Evidence map›Paper›PMID 35303181›Full record

ArticleJournal of patient-reported outcomes2022

How do patients and physicians perceive immune thrombocytopenia (ITP) as a disease? Results from Indian analysis of ITP World Impact Survey (I-WISh).

Prantar Chakrabarti, Biju George, Chandrakala Shanmukhaiah, Lalit Mohan Sharma, Shashank Udupi, Waleed Ghanima

Open access · goldAbstract read
In one paragraph

Article in Journal of patient-reported outcomes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 3 countries.

Prantar ChakrabartiDepartment of Hematology, Vivekananda Institute of Medical Sciences, Machan, L 16 Panchasayar, Kolkata, West Bengal, 700094, India.
Biju GeorgeDepartment of Hematology, CMC Vellore, Vellore, Tamil Nadu, 632004, India.
Chandrakala ShanmukhaiahDepartment of Clinical Hematology, KEM Hospital, 1902, 19th floor UG PG hostel, KEM Hospital Campus, Parel, Mumbai, Maharashtra, 400012, India.
Lalit Mohan SharmaDepartment of Medical Oncology, MG Medical College, 67/166, Sector 6, Pratap Nagar, Jaipur, Rajasthan, India.
Shashank UdupiMedical Affairs, Oncology (Hematology), Novartis Healthcare Private Limited, Inspire BKC, Part of 601 & 701, 7th Floor, Bandra Kurla Complex, Bandra (East), Mumbai, Maharashtra, 400051, India.
Waleed GhanimaDepartments of Research and Hemato-Oncology, Østfold Hospital, Østfold Hospital, PB 300, 1714, Grålum, Norway. wghanima@gmail.com.ORCID http://orcid.org/0000-0003-2225-6165
Christian Medical College, Vellore · INCollege of Medicine & JNM Hospital · INGraz University Hospital · ATNovartis (India) · INVivekananda Institute of Medical Sciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeImmune thrombocytopenia (ITP) is primarily considered a bleeding disorder; its impact on patients' health-related quality of life (HRQoL) is under-recognized. We aimed to assess how aligned patient and physician perceptions are regarding ITP-associated symptoms, HRQoL, and disease management in India.

methodsPatients and physicians (hematologists/hemato-oncologists) from India who participated in the global ITP World Impact Survey (I-WISh) were included in this subgroup analysis (survey). Physicians were recruited via a local, third party recruiter in India. In addition to completing a survey themselves, physicians were asked to invite consulting patients on a consecutive basis to complete a survey. All surveys were completely independently by the respondents online in English. The respondents took 30 min to complete the questionnaire. Patients also completed the newly developed ITP Life Quality Index (ILQI) that included 10 questions on the impact of ITP on the following: work or studies, time taken off work or education, ability to concentrate, social life, sex life, energy levels, ability to undertake daily tasks, ability to provide support, hobbies, and capacity to exercise.

resultsA total of 65 patients and 21 physicians were included in this study. Average disease duration from diagnosis-to-survey-completion was 5.3 years. The most severe symptoms reported by patients at diagnosis were menorrhagia (15 of 19 patients [79%]), anxiety surrounding unstable platelet counts (17 of 28 patients [61%]), and fatigue (27 of 46 patients [59%]); these were also the key symptoms they wanted to be resolved. In contrast, physicians perceived petechiae (19 of 21 patients [90%]), bleeding-from-gums (8 of 21 patients [86%]), and purpura (16 of 21 patients [76%]) as the most common symptoms. While the important treatment goals for patients were healthy blood counts (42 of 65 patients [65%]), improved QoL (35 of 65 patients [54%]), and prevention of worsening of ITP (33 of 65 patients [51%]), physicians' goals were reduction in spontaneous bleeding (17 of 21 physicians [81%]), better QoL (14 of 21 physicians [67%]), and symptom improvement (9 of 21 physicians [43%]). More than half the patients reported that ITP affected their work life/studies, social life, and energy levels, thereby negatively impacting their QoL. Patients were almost entirely dependent on family and friends for support.

conclusionsThis survey highlights the substantial discrepancy in patients' and physicians' perceptions regarding ITP-associated symptoms and treatment goals in India. Based on the identified gaps, educating physicians on aspects of ITP beyond bleeding, and highlighting patients' under-recognized symptoms/needs through support-systems should be prioritized in the future.

Indexed as

Disease managementHealth-related quality of life (HRQoL)Immune thrombocytopenia (ITP)IndiaITP symptomsITP World Impact Survey (I-WISh)

Identifiers

PMID35303181
PMCPMC8933602
OpenAlexW4221000017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.